Patrick Schöffski1, Michael Gordon2, David C Smith3, Razelle Kurzrock4, Adil Daud5, Nicholas J Vogelzang6, Yihua Lee7, Christian Scheffold8, Geoffrey I Shapiro9. 1. Department of General Medical Oncology, Leuven Cancer Institute, University Hospital Leuven, Leuven, Belgium. Electronic address: patrick.schoffski@uzleuven.be. 2. Pinnacle Oncology Hematology, Scottsdale, AZ, USA. Electronic address: mgordon@azpoh.com. 3. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: dcsmith@med.umich.edu. 4. Moores Cancer Center, University of California, San Diego, San Diego, CA, USA. Electronic address: rkurzrock@ucsd.edu. 5. Medical Center at Parnassus, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Adil.Daud@ucsf.edu. 6. Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV, USA. Electronic address: Nicholas.Vogelzang@usoncology.com. 7. Exelixis, Inc., South San Francisco, CA, USA. Electronic address: ewalee@yahoo.com. 8. Exelixis, Inc., South San Francisco, CA, USA. Electronic address: cscheffo@exelixis.com. 9. Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: geoffrey_shapiro@dfci.harvard.edu.
Abstract
BACKGROUND:Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types. PATIENTS AND METHODS: Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase. RESULTS: A total of 526 patients were enrolled. The highest ORR was observed in ovarian cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic breast cancer (MBC), hepatocellular carcinoma (HCC) and non-small cell lung cancer. Median duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacy results and symptomatic improvements prompted early suspension of the randomised stage and conversion to open-label non-randomised expansion cohorts. Dose reductions to manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III-IV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-plantar erythrodysesthesia syndrome (8.7%). CONCLUSIONS:Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial. TRIAL REGISTRATION NUMBER: NCT00940225.
RCT Entities:
BACKGROUND:Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types. PATIENTS AND METHODS: Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase. RESULTS: A total of 526 patients were enrolled. The highest ORR was observed in ovarian cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic breast cancer (MBC), hepatocellular carcinoma (HCC) and non-small cell lung cancer. Median duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacy results and symptomatic improvements prompted early suspension of the randomised stage and conversion to open-label non-randomised expansion cohorts. Dose reductions to manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III-IV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-plantar erythrodysesthesia syndrome (8.7%). CONCLUSIONS: Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial. TRIAL REGISTRATION NUMBER: NCT00940225.
Authors: Ursula A Matulonis; Michael W Sill; Vicky Makker; David G Mutch; Jay W Carlson; Christopher J Darus; Robert S Mannel; David P Bender; Erin K Crane; Carol Aghajanian Journal: Gynecol Oncol Date: 2018-12-23 Impact factor: 5.482
Authors: Pablo Maroto; Camillo Porta; Jaume Capdevila; Andrea B Apolo; Santiago Viteri; Cristina Rodriguez-Antona; Lidia Martin; Daniel Castellano Journal: Ther Adv Med Oncol Date: 2022-07-13 Impact factor: 5.485
Authors: Ravi A Madan; Fatima H Karzai; Munjid Al Harthy; Daniel P Petrylak; Joseph W Kim; Philip M Arlen; Inger Rosner; Marc R Theoret; Lisa Cordes; Marijo Bilusic; Cody J Peer; Nancy A Dawson; Anna Couvillon; Amy Hankin; Moniquea Williams; Guin Chun; Helen Owens; Jennifer L Marte; Min-Jung Lee; Yusuke Tomita; Akira Yuno; Jane B Trepel; Sunmin Lee; Seth M Steinberg; James L Gulley; William D Figg; William L Dahut Journal: BJU Int Date: 2020-10-23 Impact factor: 5.969